Showing 1891-1900 of 2105 results for "".
- Continuous Subcutaneous Infusion of Levodopa/Carbidopa Has Long-Term Safety in Parkinson Diseasehttps://practicalneurology.com/news/contours-subcutaneous-infusion-of-levodopacarbidopa-has-long-term-safety-in-parkinson-disease/2469868/The phase 2b BeyoND study demonstrates the infusion of levodopa/carbidopa (ND0612; Neuroderm, Israel) was safe and well tolerated over a year long period in individuals with Parkinson disease (PD) with motor fluctuations. As reported in 2021, treatment with continuous subcutaneous infusion of lev
- Ecopipam Reduced Tic Severity in Tourette Syndromehttps://practicalneurology.com/news/ecopipam-reduced-tic-severity-in-tourette-syndrome/2469866/In a clinical trial (NCT04007991) of ecopipam, children and teens (age 6 to 17 years) with Tourette syndrome who were treated with ecopipam for 3 months had improved scores on tests of tic severity after 3 months. Among those who were
- Brain-Computer Interface, Implanted Endovascularly, Allows People With Paralysis to Operate Computers With Their Thoughtshttps://practicalneurology.com/news/brain-computer-interface-implanted-endovascularly-allows-people-with-paralysis-to-operate-computers-with-their-thoughts/2469862/In a first-in-human study, 4 participants were implanted with a brain-computer interface (BCI) (Stentrode, Synchron, Brooklyn, NY) delivered via an endovascular stent to the superior sagittal sinus. The brain-computer interface allowed participants with paralysis to independently perform computer
- FDA Approves Expanded Indication of Fenfluramine for Lennox-Gastaut Syndromehttps://practicalneurology.com/news/fda-approves-expanded-indication-of-fenfluramine-for-lennox-gastaut-syndrome/2469861/The Food and Drug Administration (FDA) approved an expanded indication of fenfluramine (Fintepla; Zogenix, Emeryville, CA) to treat seizures in Lennox-Gastaut syndrome (LGS) in individuals age 2 years or more. “The approval of Fintepla for Lennox-Gastaut syndrome highlights our co
- Risdiplam Has Long-Term Efficacy and Safety in Treatment of Spinal Muscular Atrophyhttps://practicalneurology.com/news/risdiplam-has-long-term-efficacy-and-safety-in-treatment-of-spinal-muscular-atrophy/2469854/New clinical trial data for risdiplam (Evrysdi; Genentech, San Franscisco, CA) shows long-term efficacy and safety of risdiplam for up to 3 years of treatment of spinal muscular atrophy (SMA). These data come from a broad population of people with SMA2 and SMA3. In the SUNFISH stu
- Blarcamesine Treatment Shows Clinical and Biomarker Improvements in Parkinson Disease Dementiahttps://practicalneurology.com/news/blarcamesine-treatment-shows-clinical-and-biomarker-improvements-in-parkinson-disease-dementia/2469852/In a clinical trial (NCT03774459) of blacarmesine (Anavex 2-73; Anavex Life Sciences, New York, NY) for Parkinson disease dementia (PDD), clinical improvements in motor and nonmotor symptoms were seen. There was also evidence of releva
- Early Presymptomatic Treatment With Nusinersen Results Show Continued Increases in Meeting Motor Milestoneshttps://practicalneurology.com/news/early-presymptomatic-treatment-with-nusinersin-results-show-continued-increases-in-meeting-motor-milestones/2469850/Results from the NURTURE study (NCT02386553) show presymptomatic infants with spinal muscular atrophy (SMA) treated with nusinersen (Spinraza; Biogen, Cambridge MA) for up to 5.7 years (median 4.9 years) continue gaining motor function
- Atogepant Significantly Reduced Monthly Migraine Days for Chronic Migrainehttps://practicalneurology.com/news/atogepant-significantly-reduced-monthly-migraine-days-for-chronic-migraine/2469846/Atogepant (Quliptatm; AbbVie, North Chicago, IL), 60 mg once daily or 30 mg twice daily , significantly reduced monthly migraine days (MMD) compared with placebo in phase 3 trial (NCT03855137) for adults with chronic migraine. Participants (n=778) who had at least a 1-year of chronic
- Study to Assess Impact of Lifestyle Interventions to Control Epileptic Seizureshttps://practicalneurology.com/news/study-to-assess-impact-of-lifestyle-interventions-to-control-epileptic-seizures/2469839/An innovative study has launched to evaluate a possible link between epilepsy and stress. The 5-year clinical trial is the first to compare the effect of lifestyle interventions on seizure control. The study will enroll 1,000 participants with difficult-to-treat epilepsy, observe the im
- Risk-Benefit Profile of Ozanimod for Multiple Sclerosis Did Not Change With COVID-19https://practicalneurology.com/news/risk-benefit-profile-of-ozanimod-for-multiple-sclerosis-did-not-change-with-covid-19/2469834/In the open-label extension DAYBREAK study (NCT02576717) among participants in 4 clinical trials of ozanimod (Zeposia; Bristol Myers Squibb, New York, NY) for multiple sclerosis (MS), the effect of COVID-19 was evaluated. The 2,494 par